A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice

• Published in: EBioMedicine 2024-08, Vol.106 (C), p.105260, Article 105260
• Main Authors: Yang, Hui, Wang, Xinzhi, Blanco-Gómez, Adrián, He, Li, García-Sancha, Natalia, Corchado-Cobos, Roberto, Pérez-Baena, Manuel Jesús, Jiménez-Navas, Alejandro, Wang, Pin, Inman, Jamie L., Snijders, Antoine M., Threadgill, David W., Balmain, Allan, Chang, Hang, Perez-Losada, Jesus, Mao, Jian-Hua
• Format: Article
• Language: English
• Subjects: Animals; Biomarkers, Tumor - genetics; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Collaborative cross mice; Collaborative Cross Mice - genetics; Disease Models, Animal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene signature; General & Internal Medicine; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Mice; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Research & Experimental Medicine; Transcriptome; Treatment response prediction; Tumour susceptibility
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2024.105260

Deeper insights into ERBB2-driven cancers are essential to develop new treatment approaches for ERBB2+ breast cancers (BCs). We employed the Collaborative Cross (CC) mouse model to unearth genetic factors underpinning Erbb2-driven mammary tumour development and metastasis. 732 F1 hybrid female mice between FVB/N MMTV-Erbb2 and 30 CC strains were monitored for mammary tumour phenotypes. GWAS pinpointed SNPs that influence various tumour phenotypes. Multivariate analyses and models were used to construct the polygenic score and to develop a mouse tumour susceptibility gene signature (mTSGS), where the corresponding human ortholog was identified and designated as hTSGS. The importance and clinical value of hTSGS in human BC was evaluated using public datasets, encompassing TCGA, METABRIC, GSE96058, and I-SPY2 cohorts. The predictive power of mTSGS for response to chemotherapy was validated in vivo using genetically diverse MMTV-Erbb2 mice. Distinct variances in tumour onset, multiplicity, and metastatic patterns were observed in F1-hybrid female mice between FVB/N MMTV-Erbb2 and 30 CC strains. Besides lung metastasis, liver and kidney metastases emerged in specific CC strains. GWAS identified specific SNPs significantly associated with tumour onset, multiplicity, lung metastasis, and liver metastasis. Multivariate analyses flagged SNPs in 20 genes (Stx6, Ramp1, Traf3ip1, Nckap5, Pfkfb2, Trmt1l, Rprd1b, Rer1, Sepsecs, Rhobtb1, Tsen15, Abcc3, Arid5b, Tnr, Dock2, Tti1, Fam81a, Oxr1, Plxna2, and Tbc1d31) independently tied to various tumour characteristics, designated as a mTSGS. hTSGS scores (hTSGSS) based on their transcriptional level showed prognostic values, superseding clinical factors and PAM50 subtype across multiple human BC cohorts, and predicted pathological complete response independent of and superior to MammaPrint score in I-SPY2 study. The power of mTSGS score for predicting chemotherapy response was further validated in an in vivo mouse MMTV-Erbb2 model, showing that, like findings in human patients, mouse tumours with low mTSGS scores were most likely to respond to treatment. Our investigation has unveiled many new genes predisposing individuals to ERBB2-driven cancer. Translational findings indicate that hTSGS holds promise as a biomarker for refining treatment strategies for patients with BC. The U.S. Department of Defense (DoD) Breast Cancer Research Program (BCRP) (BC190820), United States; MCIN/AEI/10.13039/501100011039 (PID2020-118527RB-I00